Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-Term Immune Response and Safety After RSV Vaccination in High-Risk Transplant Recipients

  • By

  • Victoria G. Hall

  • Adrian A. Alexander

  • Madeline R. Kern-Smith

  • Faranak Mavandadnejad

  • Sarayna Bala

  • Xiaoqing Dang

  • Rujun Kang

  • Sapna Humar

  • Poramed Winichakoon

  • Rochelle Johnstone

  • Ailya Salman

  • Meghan Aversa

  • Igor Novitzky-Basso

  • Roni Bitterman

  • Pascal M. Lavoie

  • Deepali Kumar

  • Jonas Mattsson

  • Victor H. Ferreira

  • November 6, 2026

Share

  • 1

    This single-center, nonrandomized trial followed 86 lung or allogeneic hematopoietic cell transplant recipients for 12 months after 1 dose of adjuvanted RSVPreF3 vaccine.

  • 2

    Neutralizing antibody titers rose after vaccination, remained stable through 6 months, and waned by 12 months; seroconversion at 12 months was 24% in lung and 17% in alloHCT recipients.

  • 3

    Binding antibody concentrations increased after vaccination and remained above baseline at 12 months, while polyfunctional CD4+ T-cell frequencies also remained significantly above baseline.

  • 4

    Lung transplant recipients had higher antibody responses than alloHCT recipients, whereas polyfunctional CD4+ T-cell responses were comparable; RSV-specific CD8+ T-cell responses were largely undetect

  • 5

    Vaccination was well tolerated, with no vaccine-related rejection or graft-vs-host disease; the study was limited by its single-center design, modest sample, and lack of a control group.

Original Source(s)

Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients

  • by Victoria G. Hall, Adrian A. Alexander, Madeline R. Kern-Smith, Faranak Mavandadnejad, Sarayna Bala, Xiaoqing Dang, Rujun Kang, Sapna Humar, Poramed Winichakoon, Rochelle Johnstone, Ailya Salman, Meghan Aversa, Igor Novitzky-Basso, Roni Bitterman, Pascal M. Lavoie, Deepali Kumar, Jonas Mattsson, Victor H. Ferreira

  • November 6, 2026

Related Content

Much of the excess mortality in immunocompromised patients with viral severe acute respiratory infection occurs after ICU discharge

Reimagining Federal Science Advice—What to Preserve and What to Reform

Correction: β-Lactam–Induced Encephalopathy: An Underrecognized Complication Of Commonly Used Antibiotics—A Case Report